Nilotinib as first-line therapy for chronic myeloid leukemia.
Indian J Cancer
;
2011 Oct-Dec; 48(4): 438-445
Article
Dans Anglais
| IMSEAR
| ID: sea-144524
ABSTRACT
Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Pipérazines
/
Pyrimidines
/
Protein-tyrosine kinases
/
Humains
/
Résistance aux substances
/
Leucémie myéloïde chronique BCR-ABL positive
/
Survie sans rechute
/
Thérapie moléculaire ciblée
/
Animaux
/
Antinéoplasiques
langue:
Anglais
Texte intégral:
Indian J Cancer
Année:
2011
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS